Fig. 3.
CD362+ human mesenchymal stromal cells (hMSCs) decrease Escherichia coli–induced lung injury. Both CD362+ and CD362− hMSC therapy reduced the decrement in arterial oxygenation (A) and in static lung compliance (B), compared to treatment with vehicle alone (vehicle). CD362+, but not CD362−, cells attenuated the increase in lung wet:dry weight ratios (C), reduced lung Escherichia coli bacterial load (D), reduced bronchoalveolar lavage (BAL) cellular counts (E), and decreased the proportion of neutrophils in the BAL (F). Overall, the magnitude of the effect of the CD362+ was comparable to that seen with heterogeneous hMSCs. Error bars represent SD in panels A–C and E–F and represent interquartile ranges in D. n = 10 animals per group. *Significantly (P < 0.05) different from vehicle control group.